Fluid Biopsy
A Global Strategic Business Report
MCP36918
WHAT'S BEHIND OUR DATA?
140857226
DOMAIN TRANSCRIPTS6080276
BRANDS TRACKED1729341
FEATURED COMPANIES22574
TOPICS COVERED82719
MARKET SEGMENTS91
KEY INDUSTRIES1574
CURATION TEAM4761909
DECISION MAKERSEXECUTIVE ENGAGEMENTS BY TIER (55)
3
CXO5
VICE PRESIDENT10
DIRECTOR25
MANAGER12
MARKETING
REQUEST FULL-STACK INDEX
Includes 350+ pages validated sources
QUESTIONNAIRE
EXECUTIVES
DATA ROOM
HIGHLIGHTS & REPORT INDEX
Global Fluid Biopsy Market to Reach US$21.0 Billion by 2030
The global market for Fluid Biopsy estimated at US$11.4 Billion in the year 2024, is expected to reach US$21.0 Billion by 2030, growing at a CAGR of 10.6% over the analysis period 2024-2030. Lung Cancer, one of the segments analyzed in the report, is expected to record a 12.4% CAGR and reach US$8.2 Billion by the end of the analysis period. Growth in the Breast Cancer segment is estimated at 8.3% CAGR over the analysis period.
The U.S. Market is Estimated at US$3.1 Billion While China is Forecast to Grow at 14.7% CAGR
The Fluid Biopsy market in the U.S. is estimated at US$3.1 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.4 Billion by the year 2030 trailing a CAGR of 14.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.5% and 9.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.
Global Fluid Biopsy Market – Key Trends & Drivers Summarized
Why Is Fluid Biopsy Emerging as a Disruptive Force in Cancer Diagnostics?
Fluid biopsy—also known as liquid biopsy—is transforming cancer diagnostics and disease monitoring by offering a non-invasive alternative to traditional tissue biopsies. By analyzing tumor-derived components such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and microRNAs from biological fluids (mainly blood), fluid biopsy enables early cancer detection, real-time disease tracking, and therapeutic response assessment. Its ability to capture tumor heterogeneity without the need for surgical sampling is particularly valuable in metastatic and inaccessible tumor settings.
This approach is gaining prominence in oncology due to its potential for detecting minimal residual disease (MRD), identifying actionable mutations, and guiding personalized therapy decisions across various cancer types—particularly lung, breast, colorectal, and prostate cancers. Unlike tissue biopsies that may be limited by procedural risks and spatial constraints, fluid biopsy allows for repeatable sampling over the disease course. As precision medicine continues to evolve, fluid biopsy is becoming an essential tool for dynamic tumor profiling and treatment adjustment.
What Technological Innovations Are Expanding the Potential of Fluid Biopsies?
Technological advancements in molecular biology, genomic sequencing, and digital PCR have significantly expanded the accuracy and clinical utility of fluid biopsies. Next-generation sequencing (NGS) platforms can now detect low-frequency mutations in ctDNA with high sensitivity, enabling early identification of tumor-related genomic alterations. Droplet digital PCR (ddPCR) and BEAMing (Beads, Emulsion, Amplification, Magnetics) are being utilized for mutation quantification, allowing for longitudinal tracking of tumor burden and therapy response.
Microfluidics-based platforms and CTC enrichment technologies are improving the capture efficiency of rare cells and particles from blood samples. Simultaneously, AI-driven data interpretation tools are facilitating rapid analysis of complex molecular signatures, supporting real-time clinical decision-making. Advances in multiplexing and integration of biomarkers from multiple fluid types—including urine, cerebrospinal fluid, and saliva—are extending fluid biopsy’s applications beyond oncology into other domains such as prenatal screening, organ transplant monitoring, and infectious disease surveillance.
Which Clinical and Therapeutic Areas Are Accelerating Adoption of Fluid Biopsy?
Fluid biopsy is primarily utilized in oncology, where it supports early cancer screening, companion diagnostics, and resistance mutation detection. In non-small cell lung cancer (NSCLC), for example, fluid biopsy is routinely used to detect EGFR mutations and guide the use of targeted therapies. Breast and prostate cancers are also key areas where serial fluid biopsies help monitor hormone receptor status and metastatic progression without repeated imaging or surgery.
Beyond solid tumors, hematological malignancies are beginning to benefit from ctDNA-based minimal residual disease detection, particularly in leukemias and lymphomas. Clinical trials now commonly incorporate fluid biopsy endpoints to stratify patients, evaluate drug efficacy, and correlate molecular response with clinical outcomes. Meanwhile, its application in immuno-oncology is expanding as researchers use fluid biopsy to assess tumor mutational burden (TMB) and predict response to checkpoint inhibitors. The versatility and scalability of fluid biopsy are also enabling broader adoption in population screening initiatives and point-of-care diagnostic frameworks.
What Are the Main Drivers Supporting Growth in the Fluid Biopsy Market?
The growth in the fluid biopsy market is driven by several converging factors rooted in clinical utility, technological maturity, and healthcare system needs. A primary driver is the growing demand for non-invasive, patient-friendly diagnostic tools that reduce procedure-related complications and enable frequent disease monitoring. This aligns with global trends favoring personalized medicine, early intervention, and outcomes-based treatment models.
The increasing availability of advanced sequencing technologies at lower costs is making fluid biopsy more accessible to both clinicians and diagnostic laboratories. Rising cancer incidence worldwide, combined with the need for timely, molecular-level decision support, is accelerating clinical adoption. Regulatory approvals for liquid biopsy-based companion diagnostics and reimbursement support in key markets are further solidifying its role in standard oncology workflows. Additionally, robust investments in precision oncology research, biopharma collaborations, and startup innovation are fueling a dynamic and competitive ecosystem that continues to expand the frontiers of fluid biopsy applications. Collectively, these drivers position fluid biopsy as a transformative force in the future of disease detection and personalized treatment.
SCOPE OF STUDY
The report analyzes the Fluid Biopsy market by the following Segments, and Geographic Regions/Countries:
Segments:
Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Other Indications); Type (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA).
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa..
SELECT PLAYERS
Angle plc; Biocept, Inc.; Bio-Rad Laboratories, Inc.; Caris Life Sciences; CellMax Life; Cynvenio Biosystems, Inc.; Epigenomics AG; Exact Sciences Corporation; F. Hoffmann-La Roche Ltd; Freenome Holdings, Inc.; GRAIL, Inc.; Guardant Health, Inc.; Helio Health; Illumina, Inc.; Inivata Ltd; Invitae Corporation; Lucence Diagnostics Pte Ltd; Menarini Silicon Biosystems; Myriad Genetics, Inc.; Natera, Inc.; NeoGenomics Laboratories; QIAGEN N.V.; Resolution Bioscience (Agilent); Sysmex Corporation; Tempus Labs, Inc.; Thermo Fisher Scientific Inc.;
AI INTEGRATIONS
We’re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy |
| World Market Trajectories |
| How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind |
| Fluid Biopsy – Global Key Competitors Percentage Market Share in 2025 (E) |
| Competitive Market Presence - Strong/Active/Niche/Trivial for 42 Players Worldwide in 2025 (E) |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| Rising Incidence of Cancer Throws the Spotlight on Non-Invasive Diagnostic Technologies |
| Growing Clinical Focus on Real-Time Tumor Monitoring Drives Demand for Liquid Biopsy Platforms |
| Technological Advancements in Circulating Biomarker Detection Accelerate Market Expansion |
| Expansion of Precision Medicine Programs Strengthens Business Case for Fluid Biopsy Applications |
| Integration of Multi-Omics Approaches Spurs Innovation in Personalized Cancer Diagnostics |
| Increase in Pharmaceutical R&D Pipelines Boosts Utility of Fluid Biopsy in Clinical Trials |
| Emergence of cfDNA and CTC-Based Panels Expands Diagnostic Utility Beyond Oncology |
| Surge in Patient Preference for Less Invasive Procedures Generates Growth Opportunities |
| AI-Powered Data Analysis Tools Improve Accuracy and Interpretation of Fluid Biopsy Results |
| Growth in Early Cancer Screening Initiatives Drives Adoption of Blood-Based Biopsy Platforms |
| Advances in Microfluidics and NGS Technologies Enhance Sensitivity of Fluid Biopsy Systems |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Fluid Biopsy Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030 |
| World Recent Past, Current & Future Analysis for Fluid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Fluid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| World 16-Year Perspective for Fluid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| World 16-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| World 16-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Circulating Tumor Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Circulating Tumor Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| World 16-Year Perspective for Circulating Tumor Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Circulating Tumor DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Circulating Tumor DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| World 16-Year Perspective for Circulating Tumor DNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Cell-Free DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Cell-Free DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| World 16-Year Perspective for Cell-Free DNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E) |
| USA Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| USA Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| USA 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| USA Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| USA Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| USA 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Canada Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Canada 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Canada Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Canada Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Canada 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| JAPAN |
| Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E) |
| Japan Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Japan Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Japan 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Japan Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Japan Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Japan 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| CHINA |
| Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E) |
| China Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| China Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| China 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| China Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| China Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| China 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| EUROPE |
| Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E) |
| Europe Recent Past, Current & Future Analysis for Fluid Biopsy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| Europe Historic Review for Fluid Biopsy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Europe 16-Year Perspective for Fluid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030 |
| Europe Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Europe Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Europe 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Europe Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Europe Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Europe 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| FRANCE |
| Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E) |
| France Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| France Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| France 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| France Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| France Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| France 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| GERMANY |
| Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E) |
| Germany Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Germany Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Germany 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Germany Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Germany Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Germany 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Italy Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Italy 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Italy Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Italy Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Italy 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| UNITED KINGDOM |
| Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E) |
| UK Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| UK Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| UK 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| UK Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| UK Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| UK 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| SPAIN |
| Spain Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Spain Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Spain 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Spain Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Spain Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Spain 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| RUSSIA |
| Russia Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Russia Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Russia 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Russia Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Russia Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Russia 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of Europe Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Rest of Europe 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Rest of Europe Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of Europe Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Rest of Europe 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| ASIA-PACIFIC |
| Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for Fluid Biopsy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Fluid Biopsy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Asia-Pacific 16-Year Perspective for Fluid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030 |
| Asia-Pacific Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Asia-Pacific 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Asia-Pacific Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Asia-Pacific 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| AUSTRALIA |
| Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E) |
| Australia Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Australia Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Australia 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Australia Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Australia Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Australia 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| INDIA |
| Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E) |
| India Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| India Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| India 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| India Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| India Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| India 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| SOUTH KOREA |
| South Korea Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| South Korea Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| South Korea 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| South Korea Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| South Korea Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| South Korea 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| REST OF ASIA-PACIFIC |
| Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of Asia-Pacific Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Rest of Asia-Pacific 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of Asia-Pacific Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Rest of Asia-Pacific 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| LATIN AMERICA |
| Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E) |
| Latin America Recent Past, Current & Future Analysis for Fluid Biopsy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| Latin America Historic Review for Fluid Biopsy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Latin America 16-Year Perspective for Fluid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030 |
| Latin America Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Latin America Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Latin America 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Latin America Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Latin America Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Latin America 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| ARGENTINA |
| Argentina Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Argentina Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Argentina 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Argentina Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Argentina Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Argentina 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| BRAZIL |
| Brazil Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Brazil Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Brazil 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Brazil Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Brazil Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Brazil 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| MEXICO |
| Mexico Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Mexico Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Mexico 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Mexico Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Mexico Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Mexico 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| REST OF LATIN AMERICA |
| Rest of Latin America Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of Latin America Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Rest of Latin America 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Rest of Latin America Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of Latin America Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Rest of Latin America 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| MIDDLE EAST |
| Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E) |
| Middle East Recent Past, Current & Future Analysis for Fluid Biopsy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| Middle East Historic Review for Fluid Biopsy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Middle East 16-Year Perspective for Fluid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030 |
| Middle East Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Middle East Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Middle East 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Middle East Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Middle East Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Middle East 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| IRAN |
| Iran Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Iran Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Iran 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Iran Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Iran Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Iran 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| ISRAEL |
| Israel Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Israel Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Israel 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Israel Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Israel Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Israel 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| SAUDI ARABIA |
| Saudi Arabia Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Saudi Arabia Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Saudi Arabia 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Saudi Arabia Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Saudi Arabia Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Saudi Arabia 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| UNITED ARAB EMIRATES |
| UAE Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| UAE Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| UAE 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| UAE Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| UAE Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| UAE 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| REST OF MIDDLE EAST |
| Rest of Middle East Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of Middle East Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Rest of Middle East 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Rest of Middle East Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of Middle East Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Rest of Middle East 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
| AFRICA |
| Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E) |
| Africa Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Africa Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Africa 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030 |
| Africa Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Africa Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR |
| Africa 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030 |
COMPETITIVE METRICS
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]